Pajjiż: Ingilterra
Lingwa: Ingliż
Sors: MHRA (Medicines & Healthcare Products Regulatory Agency)
Edoxaban tosilate
Daiichi Sankyo UK Ltd
B01AF03
Edoxaban tosilate
30mg
Tablet
Oral
No Controlled Drug Status
Valid as a prescribable product
BNF: 02080200; GTIN: 5015494300289
1 PACKAGE LEAFLET: INFORMATION FOR THE USER LIXIANA 15 MG FILM-COATED TABLETS LIXIANA 30 MG FILM-COATED TABLETS LIXIANA 60 MG FILM-COATED TABLETS Edoxaban This medicine is subject to additional monitoring. This will allow quick identification of new safety information. You can help by reporting any side effects you may get. See the end of section 4 for how to report side effects. READ ALL OF THIS LEAFLET CAREFULLY BEFORE YOU START TAKING THIS MEDICINE BECAUSE IT CONTAINS IMPORTANT INFORMATION FOR YOU. - Keep this leaflet. You may need to read it again. - If you have any further questions, ask your doctor or pharmacist. - This medicine has been prescribed for you only. Do not pass it on to others. It may harm them, even if their signs of illness are the same as yours. - If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4. WHAT IS IN THIS LEAFLET 1. What Lixiana is and what it is used for 2. What you need to know before you take Lixiana 3. How to take Lixiana 4. Possible side effects 5. How to store Lixiana 6. Contents of the pack and other information 1. WHAT LIXIANA IS AND WHAT IT IS USED FOR Lixiana contains the active substance edoxaban and belongs to a group of medicines called anticoagulants. This medicine helps to prevent blood clots from forming. It works by blocking the activity of factor Xa, which is an important component of blood clotting. Lixiana is used in adults to: - PREVENT BLOOD CLOTS IN THE BRAIN (stroke) AND OTHER BLOOD VESSELS IN THE BODY if you have a form of irregular heart rhythm called nonvalvular atrial fibrillation and at least one additional risk factor. - TREAT BLOOD CLOTS IN THE VEINS OF THE LEGS (deep vein thrombosis) AND IN THE BLOOD VESSELS IN THE LUNGS (pulmonary embolism), and to PREVENT BLOOD CLOTS FROM RE-OCCURRING in the blood vessels in the legs and/or lungs. 2 2. WHAT YOU NEED TO KNOW BEFORE YOU TAKE LIXIANA DO NOT TAKE LIXIANA: - if you are allergic to edoxaban or any of the other i Aqra d-dokument sħiħ
OBJECT 1 LIXIANA 30MG FILM-COATED TABLETS Summary of Product Characteristics Updated 31-Jul-2017 | Daiichi Sankyo UK Limited This medicinal product is subject to additional monitoring. This will allow quick identification of new safety information. Healthcare professionals are asked to report any suspected adverse reactions. See section 4.8 for how to report adverse reactions. 1. Name of the medicinal product Lixiana 30 mg film-coated tablets 2. Qualitative and quantitative composition Each film-coated tablet contains 30 mg edoxaban (as tosilate). For the full list of excipients, see section 6.1. 3. Pharmaceutical form Film-coated tablet. Pink, round-shaped film-coated tablets (8.5 mm diameter) debossed with “DSC L30”. 4. Clinical particulars 4.1 Therapeutic indications Prevention of stroke and systemic embolism in adult patients with nonvalvular atrial fibrillation (NVAF) with one or more risk factors, such as congestive heart failure, hypertension, age ≥ 75 years, diabetes mellitus, prior stroke or transient ischaemic attack (TIA). Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults (see section 4.4 for haemodynamically unstable PE patients). 4.2 Posology and method of administration Posology _Prevention of stroke and systemic embolism_ The recommended dose is 60 mg edoxaban once daily. Therapy with edoxaban in NVAF patients should be continued long term. _Treatment of DVT, treatment of PE and prevention of recurrent DVT and PE (VTE)_ The recommended dose is 60 mg edoxaban once daily following initial use of parenteral anticoagulant for at least 5 days (see section 5.1). Edoxaban and initial parenteral anticoagulant should not be administered simultaneously. The duration of therapy for treatment of DVT and PE (venous thromboembolism, VTE), and prevention of recurrent VTE should be individualised after careful assessment of the treatment benefit against the risk for bleeding (see section 4.4). Short duration of therapy (at least 3 months) sh Aqra d-dokument sħiħ